---
title: "AI governance for healthcare and pharma — VERITRAIL"
h1: "AI governance for healthcare and life sciences"
slug: /industries/healthcare-pharma/
description: "VERITRAIL for healthcare providers, pharma and life sciences: govern clinical, research and operational AI with evidence on purpose, data, oversight and change."
section: industries
nav_label: "Healthcare & pharma"
nav_order: 20
template: page
schema_type: WebPage
primary_cta: baseline
secondary_cta: assessment
faq:
  - q: "Can VERITRAIL tell us whether our AI is a medical device?"
    a: "No. Whether software qualifies as a medical device depends on its intended purpose and the applicable device regulations, and is a regulatory determination. VERITRAIL records intended purpose and flags systems for regulatory review (EI-04, AO-07)."
  - q: "How does VERITRAIL work with GxP computerized system validation?"
    a: "VERITRAIL does not replace validation. Its change triggers (GL-04), validation evidence (GL-05) and technical documentation (GL-06) can be aligned with your existing validation and quality processes so that AI-specific changes — such as prompt or model updates — are not missed."
updated: 2026-10-21
---

Healthcare and life-sciences organizations face a concentrated version of every AI governance challenge: sensitive health data, decisions that can affect patient safety, established quality and validation regimes, and a fast-growing population of generative AI tools in clinical documentation, research and operations.

## Priority use cases

| Use case | Why it needs governance | Likely tier |
|---|---|---|
| Clinical documentation and ambient scribing | Health data in prompts; accuracy of clinical records; clinician over-reliance | High |
| Clinical decision support and triage | Potential patient-safety impact; may fall within medical-device rules depending on intended purpose | High or Prohibited-review pending regulatory review |
| Pharmacovigilance case intake and literature screening | Regulated process; missed signals; validation expectations | High |
| Clinical trial operations (site selection, patient matching) | Fairness and representativeness; special-category data | Medium to High |
| Medical information and patient-facing assistants | Transparency to patients; harmful or off-label content | High |
| Internal productivity (summaries, drafting, coding assistants) | Data leakage; shadow AI | Low to Medium |

## Regulatory context, carefully stated

- **Medical-device software rules.** In several jurisdictions, software — including AI — intended for diagnosis, prevention, monitoring or treatment can be regulated as a medical device (for example under the EU Medical Device Regulation or by the US FDA). Qualification depends on intended purpose. AI that is a safety component of, or is itself, a product covered by EU harmonization legislation may also be high-risk under the EU AI Act.
- **Health data protection.** Health data is special-category data under the GDPR and protected health information under HIPAA in the US; other jurisdictions have equivalents.
- **Quality and validation.** GxP environments expect computerized systems to be validated and changes controlled — AI components, prompts and models included.

VERITRAIL does not determine how these regimes apply. It ensures the facts that drive those determinations are recorded and that systems are routed to the right reviewers.

## VERITRAIL emphasis

- **Intended purpose discipline (EI-04).** Precise intended-purpose statements, foreseeable misuse and out-of-scope uses — the foundation for both device qualification analysis and EU AI Act classification.
- **Data and privacy (EI-06, IS-03, IS-04).** Lineage of health data, privacy impact assessment, and redaction before any external model call.
- **Human oversight (IS-09).** Clinician review designs that account for automation bias, with override and escalation.
- **Change control (GL-04, GL-05).** Model, prompt and data changes treated as validated-system changes with reassessment triggers.
- **Vendor AI (GL-11, EI-08).** Ambient scribing and clinical AI vendors assessed for data use, model change notice and incident notification.

{{controls:EI-04,IS-03,IS-04,IS-09,GL-04,GL-11}}

## Typical first 90 days

| Days | Focus | Outputs |
|---|---|---|
| 1–30 | Inventory clinical, research and operational AI including vendor tools; screen for potential device or high-risk relevance; stand up governance forum with clinical safety and quality representation | Inventory with owners; regulatory review list; forum charter |
| 31–60 | Pre-deployment assessments for High-tier systems; privacy assessments; redaction for generative AI handling health data; change triggers aligned with validation SOPs | Assessments; redaction configuration; updated change procedure |
| 61–90 | Oversight designs for clinical-facing AI; runtime guardrails for patient-facing assistants; evidence pack for the highest-risk system | Oversight designs; draft Shield policies; first evidence pack |

{{disclaimer}}

{{cta:baseline}}
